Compare Adaptive Biotechnologies Corp (ADPT) vs Sanofi SA (SNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sanofi SA — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Sanofi SA trades at $42.85 (market cap $103.29B). The key difference: Sanofi SA is far larger — about 31× Adaptive Biotechnologies Corp's market cap, and Sanofi SA pays a 5.63% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SNY | |
|---|---|---|
Market Cap | $3.33B | $103.29B |
Sector | Health | Health |
52-Week High | $22.37 | $52.34 |
52-Week Low | $10.24 | $41.33 |
Enterprise Value | $3.19B | $119.78B |
Dividend Yield | — | 5.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SNY trades at $42.98, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results with EPS of $1.10 beating expectations of $1.06, continuing a trend of positive surprises. Revenue grew to $46.72 billion in 2025 with net income margin improving to 16.72%. Recent developments include EU approval for Cenrifki in multiple sclerosis and FDA approval for Tzield expansion in pediatric diabetes treatment.
SNY presents a mixed investment case with solid fundamentals offset by technical weakness. The stock trades at reasonable valuations (P/E 18.9, P/S 1.92) with strong profitability metrics, but faces near-term headwinds from an antitrust probe and bearish technical indicators. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism amid regulatory uncertainties and pipeline execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
